Patient characteristics at conditioning for CI
| . | CAR T-cells, n (%) (n = 30) . | alloHCT, n (%) (n = 39) . | P* . |
|---|---|---|---|
| Age, y | .049 | ||
| Median | 55 | 45 | |
| Range | 20-73 | 23-67 | |
| Male sex | 22 (73) | 26 (67) | .61 |
| Diagnosis | .20 | ||
| DLBCL | 23 (77) | 23 (59) | |
| tFL | 2 (7) | 9 (23) | |
| PMBCL | 3 (10) | 1 (3) | |
| HGBCL-DH | 1 (3) | 3 (8) | |
| Other | 1(3)† | 3 (8)‡§ | |
| Type of first-line failure | .0038 (primary refractory vs other) | ||
| Primary refractory | 20 (67) | 12 (31) | |
| Early relapse (7-12 mo from start of first line) | 5 (17) | 14 (36) | |
| Late relapse | 5 (17) | 13 (33) | |
| Prior no. of lines | .19 (.076 [2 vs >2 lines]) | ||
| Median | 3.5 | 3 | |
| Range | 2-7 | 2-8 | |
| Prior autoHCT | 5 (17) | 17 (44) | .021 |
| Prior alternative CI | 4 (13) | 4 (18)‖ | |
| No. of bridging lines | .0032 (0 vs >0) | ||
| 0 | 10 (33) | 2 (5) | |
| 1 | 15 (50) | 24 (62) | |
| >1 | 5 (17) | 13 (33) | |
| Bridging regimens | .27 (immunotoxins and/or ibrutinib yes/no) | ||
| CIT | 7 (23) | 30 (77) | |
| Dexamethasone ± rituximab | 6 (20) | 4 (10) | |
| Immunotoxins (CD30, CD79) | 7 (23) | 2 (5) | |
| Ibrutinib | 4 (13) | 5 (13) | |
| Radiotherapy | 3 (10) | 5 (13) | |
| Other | 1 (3) | 1 (3) | |
| Time from indication to CI, d | .0003 | ||
| Median | 72 | 114 | |
| Range | 35-285 | 36-451 | |
| HCT comorbidity index | .81 (0 vs >0) | ||
| 0 | 18 (60) | 21/38 (55) | |
| 1-2 | 5 (17) | 11/38 (30) | |
| >2 | 7 (23) | 6/38 (16) | |
| PS ≥2 | 3 (10) | 4 (10) | 1.0 |
| sIPI high intermediate/ high | 16 (53) | 15/37 (41) | .33 |
| Bulk >10 cm | 7 (20) | 1 (3) | .018 |
| ZUMA-1 ineligible¶ | 19 (63) | 19/37 (51) | .81 |
| Disease status | .0008 (PD/SD vs CR/PR) | ||
| PD | 21 (70) | 7/38 (18) | |
| SD | 5 (17) | 6/38 (16) | |
| PR | 3 (10) | 14/38 (37) | |
| CR | 1 (3) | 11/38 (29) | |
| LDH elevated | 15 (50) | 14 (36) | .33 |
| Conditioning | — | ||
| NMA | 30 (100) | ||
| RIC | — | 9 (23) | |
| MAC | — | 30 (77) | |
| CAR/donor type | — | ||
| Tisa-cel 4 (13) | MRD 5 (13) | ||
| Axi-cel 26 (87) | MUD 15 (38) | ||
| MMUD 10 (26) | |||
| MMRD 9 (23) | |||
| Calendar year of CI | — | ||
| Median | 2019 | 2014 | |
| Range | 2018-2020 | 2005-2019 |
| . | CAR T-cells, n (%) (n = 30) . | alloHCT, n (%) (n = 39) . | P* . |
|---|---|---|---|
| Age, y | .049 | ||
| Median | 55 | 45 | |
| Range | 20-73 | 23-67 | |
| Male sex | 22 (73) | 26 (67) | .61 |
| Diagnosis | .20 | ||
| DLBCL | 23 (77) | 23 (59) | |
| tFL | 2 (7) | 9 (23) | |
| PMBCL | 3 (10) | 1 (3) | |
| HGBCL-DH | 1 (3) | 3 (8) | |
| Other | 1(3)† | 3 (8)‡§ | |
| Type of first-line failure | .0038 (primary refractory vs other) | ||
| Primary refractory | 20 (67) | 12 (31) | |
| Early relapse (7-12 mo from start of first line) | 5 (17) | 14 (36) | |
| Late relapse | 5 (17) | 13 (33) | |
| Prior no. of lines | .19 (.076 [2 vs >2 lines]) | ||
| Median | 3.5 | 3 | |
| Range | 2-7 | 2-8 | |
| Prior autoHCT | 5 (17) | 17 (44) | .021 |
| Prior alternative CI | 4 (13) | 4 (18)‖ | |
| No. of bridging lines | .0032 (0 vs >0) | ||
| 0 | 10 (33) | 2 (5) | |
| 1 | 15 (50) | 24 (62) | |
| >1 | 5 (17) | 13 (33) | |
| Bridging regimens | .27 (immunotoxins and/or ibrutinib yes/no) | ||
| CIT | 7 (23) | 30 (77) | |
| Dexamethasone ± rituximab | 6 (20) | 4 (10) | |
| Immunotoxins (CD30, CD79) | 7 (23) | 2 (5) | |
| Ibrutinib | 4 (13) | 5 (13) | |
| Radiotherapy | 3 (10) | 5 (13) | |
| Other | 1 (3) | 1 (3) | |
| Time from indication to CI, d | .0003 | ||
| Median | 72 | 114 | |
| Range | 35-285 | 36-451 | |
| HCT comorbidity index | .81 (0 vs >0) | ||
| 0 | 18 (60) | 21/38 (55) | |
| 1-2 | 5 (17) | 11/38 (30) | |
| >2 | 7 (23) | 6/38 (16) | |
| PS ≥2 | 3 (10) | 4 (10) | 1.0 |
| sIPI high intermediate/ high | 16 (53) | 15/37 (41) | .33 |
| Bulk >10 cm | 7 (20) | 1 (3) | .018 |
| ZUMA-1 ineligible¶ | 19 (63) | 19/37 (51) | .81 |
| Disease status | .0008 (PD/SD vs CR/PR) | ||
| PD | 21 (70) | 7/38 (18) | |
| SD | 5 (17) | 6/38 (16) | |
| PR | 3 (10) | 14/38 (37) | |
| CR | 1 (3) | 11/38 (29) | |
| LDH elevated | 15 (50) | 14 (36) | .33 |
| Conditioning | — | ||
| NMA | 30 (100) | ||
| RIC | — | 9 (23) | |
| MAC | — | 30 (77) | |
| CAR/donor type | — | ||
| Tisa-cel 4 (13) | MRD 5 (13) | ||
| Axi-cel 26 (87) | MUD 15 (38) | ||
| MMUD 10 (26) | |||
| MMRD 9 (23) | |||
| Calendar year of CI | — | ||
| Median | 2019 | 2014 | |
| Range | 2018-2020 | 2005-2019 |
CIT, chemoimmunotherapy; MAC, myeloablative conditioning; MMRD, mismatched related donor (haploidentical); MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; NMA, nonmyeloablative; RIC, reduced-intensity conditioning.
For comparison CAR T cells vs alloHCT >2L.
DLBCL: leg type.
DLBCL: transformed from marginal zone lymphoma.
Gray zone lymphoma.
One patient received tisagenlecleucel (without durable response) in a clinical trial in a different center after an initially unsuccessful donor search in our institution.
Disregarding n of failed lines.